Cats may not look like they’re sniffing out mysteries, but their noses are constantly at work—mapping the world, reading signals, and even picking up on your emotions. With up to 200 million ...

Find patient medical information for Insulin Glargine on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

Dive Brief: GoodRx has announced a collaboration with Sanofi to offer the drugmaker’s Lantus brand of insulin for $35 a month at tens of thousands of U.S. pharmacies, regardless of consumers ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

Currently, an estimated 37.3 million Americans (approximately 11.3% of the U.S. population) have diabetes, and roughly 8.4 million of them use insulin, according to the American Diabetes Association.

Lantus (insulin glargine) is a prescription drug that’s used to help manage blood sugar levels in people with diabetes. This drug can interact with alcohol, other medications, and some supplements.

Sanofi intends to cut its US list price for Lantus (insulin glargine injection) by 78% and cap out-of-pocket costs at $35 for all patients with commercial insurance. Sanofi announced on March 16, 2023 ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...

Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.

Sanofi plans to take a 78% list-price reduction on Lantus, the company’s most widely used insulin in the U.S., and a 70% cut on its Apidra product starting in January 2024, the company said ...